Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Solid BiosciencesSLDB +2.26%34 PB Ratio is 2.55 as of Aug. 13, 2026, which is 305% above its 10-year median of 0.63. GuruFocus rates SLDB with a GF Score™ of 34/100. The stock has 2 warning signs investors should review. Among 1,222 Biotechnology companies, Solid Biosciences ranks worse than 57.28% on this metric.
Solid Biosciences Inc stock PB Ratio (=3.41) is close to 10-year high of 3.41.
The historical rank and industry rank for Solid Biosciences's PB Ratio or its related term are showing as below:
SLDB'
s PB Ratio Range Over the Past 10 Years
Min: 0.2 Med: 0.63 Max: 3.52
Current: 3.49
During the past 11 years, Solid Biosciences's highest PB Ratio was 3.52. The lowest was 0.20. And the median was 0.63.
SLDB's PB Ratio is ranked worse than 57.28% of 1222
companies
in the Biotechnology industry
Industry Median: 2.92
vs SLDB: 3.49
During the past 12 months, Solid Biosciences's average Book Value Per Share Growth Rate was -21.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -40.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -41.10% per year.
During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of Solid Biosciences was -18.90% per year. The lowest was -50.70% per year. And the median was -35.70% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Solid Biosciences PB Ratio Related Terms
Solid Biosciences PB Ratio Historical Data
* Premium members only.
The historical data trend for Solid Biosciences's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Solid Biosciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Solid Biosciences PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Solid Biosciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where Solid Biosciences's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Solid Biosciences (SLDB) has a PB Ratio of 2.55 as of Aug. 13, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Solid Biosciences and its competitors. This is 305% above median its historical median of 0.63. Over the past decade, Solid Biosciences' PB Ratio has ranged from 0.20 to 3.52. According to the industry distribution chart, Solid Biosciences ranks #700 out of 1222 companies in the Biotechnology industry, placing it in the top 57.3%.
Is Solid Biosciences' PB Ratio too high?
Solid Biosciences' current PB Ratio of 2.55 is 305% above median its 10-year median of 0.63. Over the past 10 years, this metric has ranged from a low of 0.20 to a high of 3.52. The Biotechnology industry median PB Ratio is 2.92. Solid Biosciences' value of 2.55 is 12.7% below this industry median. Based on the distribution chart, Solid Biosciences ranks #700 out of 1222 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Solid Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Solid Biosciences' PB Ratio compare to MNPR and DSGN?
According to the Biotechnology industry distribution chart, Solid Biosciences ranks #700 out of 1222 companies for PB Ratio. This places Solid Biosciences in the lower half of its industry. The industry median PB Ratio is 2.92. Solid Biosciences' value of 2.55 is 12.7% below this benchmark. Historically, Solid Biosciences' own PB Ratio has ranged from 0.20 to 3.52 over the past decade. While the company's 10-year median is 0.63 vs. the industry median of 2.92, Solid Biosciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.92, based on 1,222 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Solid Biosciences's current PB Ratio of 2.55 is 12.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Solid Biosciences and its competitors. For the Biotechnology industry, the median PB Ratio is 2.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Solid Biosciences's current PB Ratio is 2.55, which is 305% above median its own 10-year median of 0.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solid Biosciences stock overvalued right now?
Solid Biosciences (SLDB) has a current PB Ratio of 2.55. The current PB Ratio is 2.55, which is 305% above median its 10-year median of 0.63 and 12.7% below the Biotechnology industry median of 2.92. Solid Biosciences' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Solid Biosciences (SLDB), the current PB Ratio is 2.55 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
34GF Score
Get the complete analysis for SLDB
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLDB has been successfully added to your 
